Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formulation Bridging and Food Effect of PBI-200 in Healthy Volunteers
NCT05690932Phase 1Completed
- Sponsor
- Pyramid Biosciences
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paltimatrectinib in solid tumor (5 arms), sponsored by Pyramid Biosciences. Primary endpoints: Maximum Plasma Concentration at 8 days, Area Under the Concentration-Time Curve from time zero to last measurable concentration at 8 days and 1 more. Started Feb 2022; status: completed.
02
Drugs
paltimatrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05690932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690932.